As the number of relevant studies about SGLT-2 inhibitors on UACR in T2DM patients were limited on account of the current SGLT-2 inhibitors treatment for UACR in T2DM patients was a new discovery. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.